Welcome to our dedicated page for CapsoVision SEC filings (Ticker: CV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CapsoVision, Inc. filings document a commercial-stage medical technology company focused on AI-enabled capsule endoscopy and gastrointestinal imaging. The company’s SEC record includes registration statements for common stock offerings and resale registration matters, 8-K reports on financial results, private placement financing, material development agreements and FDA-related product updates.
CapsoVision’s proxy materials cover annual meeting voting, board matters and public-company governance. Other disclosures address the company’s capital structure, common stock issuances, executive officer appointments, equity incentive arrangements, indemnification agreements, operating results and development spending tied to CapsoCam Plus®, CapsoCam Colon™ and related imaging technology.
CapsoVision, Inc director David Stanley Shields filed an initial ownership report on Form 3. The filing indicates that he does not beneficially own any shares of CapsoVision common stock, as confirmed by a footnote stating that no securities are beneficially owned.
CapsoVision, Inc. appointed gastroenterologist Dr. David S. Shields to its Board of Directors as a Class I director and member of the Compensation Committee, effective July 1, 2026, filling the vacancy created by the resignation of Dr. Joanne Imperial.
The Board determined that Dr. Shields is an independent director and he will receive the company’s standard non-employee director compensation and a standard indemnification agreement. Separately, CapsoVision entered into a consulting agreement under which Dr. Shields will provide clinical consulting and industrial affiliation services at US$600 per hour for up to 3 hours per work week.
Dr. Imperial stepped down from the Board and the Compensation Committee, effective July 1, 2026, without any disagreement regarding the company’s operations, policies or practices. Under an amended and restated consulting agreement dated July 2, 2026, she will continue as an independent consultant at US$600 per hour for up to 5 hours per work week and received an option to purchase 10,000 shares of common stock, vesting over four years, as compensation for her services.
CapsoVision, Inc director Joanne Carol Imperial reported a routine equity compensation event. On June 30, she exercised previously granted Restricted Stock Units (RSUs), receiving 2,022 shares of common stock at no cash cost to her as part of an equity incentive grant.
The filing shows she now directly owns 3,709 shares of CapsoVision common stock. The RSU award was originally granted on March 19, 2026 using a fair market value of $6.18 per share, and vests in two installments each year, with this report reflecting the June 30 vesting portion.
CapsoVision, Inc director Joanne Carol Imperial reported an open-market sale of 1,200 shares of Common Stock on June 8, 2026 at an average price of $7.1555 per share. After this transaction, she directly holds 1,687 shares of CapsoVision stock.
The amended Form 4 notes that the filing is being made late because the company was not made aware of the reportable securities sale within the required timeframe.
CapsoVision director Tsai Chen Lung increased his direct equity stake through RSU vesting and option exercise. On June 30, he exercised derivative awards to acquire 2,022 shares of Common Stock at $7.58 per share. These shares came from Restricted Stock Units previously granted as part of equity incentive awards.
The RSUs were granted using a fair market value of $6.18 per share and vest 50% on June 30 and 50% on December 31 of the applicable year. This filing reflects vesting of one-half of the original RSU grant and delivery of the underlying shares. After the transactions, he holds 4,929 Common shares directly and 2,023 RSUs that remain outstanding.
CapsoVision, Inc director Kuo Hui Ying exercised restricted stock units to acquire 2,022 shares of common stock. The RSUs converted at a stated price of $7.58 per share, increasing the director’s direct common stock holdings to 15,263 shares following the transaction.
The RSUs were granted as part of equity incentive awards using a fair market value of $6.18 per share on March 19, 2026. The grant vests 50% of the RSUs on June 30 and 50% on December 31 of the applicable year, and this transaction reflects vesting of one-half of the original grant and receipt of the underlying shares, with 2,023 RSUs remaining outstanding.
CapsoVision, Inc director King Wen-Herng Henry exercised restricted stock units to acquire 2,022 shares of Common Stock on June 30, 2026. The shares were acquired at a reported transaction price of $7.58 per share through the conversion of RSUs granted as equity compensation.
The RSUs were originally granted on March 19, 2026 using a fair market value of $6.18 per share and vest in two equal installments, on June 30 and December 31 of the applicable year. This transaction reflects vesting of one-half of the original RSU grant and the delivery of the underlying shares.
Following the transaction, Henry directly holds 25,619 shares of CapsoVision common stock and 2,023 RSUs, indicating remaining unvested equity from the same or other awards.
CapsoVision director Michele Harari reported the vesting of equity incentives that converted into common stock. On June 30, 2026, 2,022 Restricted Stock Units (RSUs) converted into 2,022 shares of CapsoVision common stock at a stated price of $0.00 per share.
These RSUs were part of an equity incentive grant made on March 19, 2026, using a fair market value of $6.18 per share. After the transaction, Harari directly holds 61,065 shares of common stock and 2,023 RSUs that remain outstanding and unvested.
CapsoVision, Inc director Julia S. Gouw exercised Restricted Stock Units to acquire additional common shares as part of her equity compensation. On 2026-06-30, she converted 2,022 RSUs into 2,022 shares of common stock, an exercise classified as a derivative conversion rather than an open-market purchase or sale.
The RSUs were originally granted on 2026-03-19 using a fair market value of $6.18 per share and vest in two equal installments on June 30 and December 31 of the applicable year. This transaction reflects the vesting of one half of the original grant and the delivery of the underlying shares. Following the transaction, Gouw directly holds 4,909 common shares and 2,023 RSUs, highlighting a compensation-driven increase in her equity stake rather than a discretionary market trade.
CapsoVision, Inc. reported the voting results from its 2026 annual meeting of stockholders held on June 11, 2026. Stockholders re-elected three Class I directors—Joanne Imperial, M.D., Wen-Herng (Henry) King, and Michele Harari—to serve until the 2029 annual meeting.
Support for each director was strong, with between 32,060,734 and 32,066,645 votes cast "for" and between 64,536 and 70,447 votes withheld, plus 2,244,596 broker non-votes for each nominee. Stockholders also ratified the appointment of Baker Tilly US, LLP as the company’s independent registered public accounting firm for the 2026 fiscal year, with 34,321,524 votes for, 154 against, and 54,099 abstentions.